TesamorelinDosage, Side Effects & Legal Status
Tesamorelin is the one peptide on this site with genuine FDA approval: as Egrifta/Egrifta SV/Egrifta WR, it's indicated for reducing excess visceral abdominal fat in HIV patients with lipodystrophy, backed by two completed Phase 3 randomized trials. What drives most of the search volume for "tesamorelin dosage" today isn't that approved use, it's bodybuilders and anti-aging users buying unbranded research-peptide tesamorelin off-label for general fat loss, a use case none of the pivotal trials tested.
Reviewed by the PepGuard team · Last reviewed Jul 28, 2026
Synthetic 44-amino-acid analog of human growth-hormone-releasing hormone (GHRH 1-44), with an added N-terminal hexenoyl group that slows enzymatic degradation · also sold as Egrifta, Egrifta SV, Egrifta WR, TH9507
Photo: Madeline Liu / UnsplashThe studies behind the headline.
Results are reported as published. A result in one population does not establish a benefit in another.
| Study | Population | Observed result | Limit |
|---|---|---|---|
| EGRIFTA SV prescribing information | Adults with HIV and lipodystrophy in two 26-week placebo-controlled studies | Injection-site reactions occurred in 17% with tesamorelin versus 6% with placebo; peripheral edema was 6% versus 2%. | These safety data do not describe healthy adults using unbranded products for fat loss. |
| NEJM pivotal trial | People with HIV-associated abdominal fat accumulation | The trial evaluated a growth-hormone-releasing factor for visceral-fat reduction at 26 weeks. | It was not a general weight-loss or anti-aging study. |
Tesamorelin is not interchangeable with a GH-axis stack
Tesamorelin is an FDA-approved GHRH analogue for one HIV-associated indication. CJC-1295 and ipamorelin are different compounds with different evidence and regulatory histories.
Read the CJC-1295 + ipamorelin evidence reportWhat the literature and self-reports actually say.
| What's cited | Range |
|---|---|
| FDA-approved dose (Egrifta SV) | 1.4 mg, subcutaneous, once daily |
| FDA-approved dose (Egrifta WR) | 1.28 mg, subcutaneous, once daily |
| Original approved formulation (Egrifta, discontinued) | 2 mg, subcutaneous, once daily |
| Commonly cited off-label protocol (bodybuilding/anti-aging, anecdotal) | 1-2 mg/day, sometimes reduced to 1 mg if IGF-1 runs high |
The FDA-approved dose is a real, label-derived figure, not a community estimate: 1.4 mg/day (Egrifta SV) or 1.28 mg/day (Egrifta WR), injected subcutaneously, studied in HIV patients with lipodystrophy. Off-label protocols circulating for bodybuilding, fat loss, or anti-aging use in non-HIV, non-clinical settings generally cite a similar 1-2 mg/day range, sometimes reduced to 1 mg if IGF-1 rises above the normal range on follow-up labs, but that reduction rule is anecdotal, not from a trial.
Signal strength, not just a list.
How often each effect shows up in the available sources, and how solid that evidence actually is.
| Signal | Frequency | Context |
|---|---|---|
| Injection site reaction | commonly reported | 17% of tesamorelin-treated patients vs. 6% on placebo in the 26-week pivotal trial data (FDA label). |
| Arthralgia (joint pain) | commonly reported | 13% on tesamorelin vs. 11% on placebo, FDA label. |
| Peripheral edema | occasionally reported | 6% on tesamorelin vs. 2% on placebo, FDA label. |
| Hypersensitivity reaction (pruritus, erythema, flushing, urticaria, rash) | occasionally reported | Reported in about 4% of patients across clinical trials, per FDA label. |
| New-onset hyperglycemia / diabetes signal | rarely reported | A cited FDA post-marketing analysis found an odds ratio of roughly 3.4-3.6 for new diabetes diagnosis vs. placebo; elevated IGF-1 from GHRH stimulation is the proposed mechanism. |
| Effects in non-HIV populations using it off-label for fat loss | unknown / not studied | Every completed pivotal trial enrolled HIV patients with lipodystrophy. There is no completed trial of tesamorelin for general fat loss or anti-aging in healthy adults, which is the population most commonly searching for its dosage today. |
FDA-approved (as Egrifta/Egrifta SV/Egrifta WR) for HIV-associated lipodystrophy. Not approved, and not a compliant compounding substance, for any other use.
Tesamorelin was approved by the FDA in 2010 under a New Drug Application (Egrifta, NDA 022505). Under the BPCIA's March 2020 transition provision, which "deemed" approved protein-based drug applications to be biologics licenses, tesamorelin's approval effectively became a biologic license rather than a small-molecule NDA. That matters for the dosage searches driving traffic to pages like this one: because it's regulated as a biologic and not on FDA's 503A bulk-substance list, tesamorelin is not the kind of compound a compounding pharmacy can legally formulate from raw peptide the way some clinics do with unapproved research peptides. The unbranded "tesamorelin" sold by research-chemical vendors for bodybuilding or anti-aging use is not the approved product and doesn't carry its regulatory backing, regardless of what the label on the vial claims.
Every claim above, traced back.
Primary studies, reviews, regulatory pages, and trial registries. Click through and check them yourself.
Tesamorelin questions, answered.
Yes, for one specific use: as Egrifta, Egrifta SV, or Egrifta WR, it's approved to reduce excess visceral abdominal fat in HIV patients with lipodystrophy. That approval doesn't extend to using tesamorelin for general fat loss, bodybuilding, or anti-aging in people without HIV, which is not a use any pivotal trial tested.
1.4 mg/day subcutaneously for Egrifta SV, or 1.28 mg/day for the newer Egrifta WR formulation. The original Egrifta formulation, since discontinued, was dosed at 2 mg/day. These are the doses studied in the pivotal trials, not a recommendation for off-label use.
Not in any regulatory sense. Egrifta is an approved, biologics-licensed product manufactured under FDA oversight. Unbranded tesamorelin sold as a research chemical is a different supply chain entirely, without the manufacturing controls, purity testing, or regulatory backing that come with the approved product, regardless of what the vendor's marketing claims.
For its approved indication, its safety profile is better characterized than almost any other peptide discussed on this site, thanks to two completed Phase 3 trials. The most notable signals are injection site reactions (17% vs. 6% placebo), joint pain, and an FDA post-marketing analysis flagging a higher rate of new-onset hyperglycemia. None of that data covers the off-label fat-loss use in non-HIV adults that most people searching for tesamorelin dosage are actually asking about.
Keep researching.
This is a preview of the Tesamorelin report.
Create your account to check any peptide against the full research base.